Dendritic cell-based immunotherapy for the treatment of hematological malignancies.
Dendritic cells (DCs) are professional antigen-presenting cells and are frequently used in current immunotherapy protocols. The administration of DCs loaded with tumor-associated proteins or peptides results in the induction of immune responses against different types of malignant cells. Methods for large-scale generation of DCs in a sufficient quality and quantity have permitted their use in clinical experiments. DC-based vaccines have already shown promise in follicular non-Hodgkin's lymphoma, and to some extent, in other hematological malignancies. Several strategies have been developed to boost their potency as a new and relatively non-toxic treatment modality. Our review focuses on clinical trials using DCs in the treatment of hematologic malignancies and on recent studies of the immunophenotype, development, and maturation of DCs may have an important impact on designing DC-based antitumor vaccines.
Laboratory of Experimental Hematology and Immunotherapy, Department of Clinical Hematology, Masaryk University Hospital, Brno, Czech Republic. tbuchler@fnbrno.cz
Tomas
T
Büchler
Jaroslav
J
Michalek
Lucie
L
Kovarova
Romana
R
Musilova
Roman
R
Hajek
D000818:Animals; D000951:Antigens, Neoplasm / Q000276:immunology*; D017209:Apoptosis; D019496:Cancer Vaccines / Q000627:therapeutic use*; D003713:Dendritic Cells / Q000145:classification / Q000276:immunology / Q000637:transplantation*; D005544:Forecasting; D019337:Hematologic Neoplasms / Q000276:immunology / Q000628:therapy*; D006689:Hodgkin Disease / Q000276:immunology / Q000628:therapy; D006801:Humans; D016130:Immunophenotyping; D007167:Immunotherapy / Q000379:methods*; D007938:Leukemia / Q000628:therapy; D008213:Lymphocyte Activation; D008228:Lymphoma, Non-Hodgkin / Q000276:immunology / Q000628:therapy; D009101:Multiple Myeloma / Q000628:therapy; D016176:T-Lymphocyte Subsets / Q000276:immunology; D014611:Vaccination
D000951:Antigens, Neoplasm; D019496:Cancer Vaccines